Use of Palliative Radiotherapy Among Patients With Metastatic Non-Small-Cell Lung Cancer
- 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (United States)
- 2. Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, MI (United States)
- 3. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (United States)
- 4. Department of Health Management and Policy, University of Michigan, Ann Arbor, MI (United States)
Description
Purpose: Radiotherapy (RT) is known to effectively palliate many symptoms of patients with metastatic non-small-cell lung cancer (NSCLC). Anecdotally, RT is believed to be commonly used in this setting, but limited population-based data are available. The objective of this study was to examine the utilization patterns of palliative RT among elderly patients with Stage IV NSCLC and, in particular, to identify factors associated with its use. Methods and Materials: A retrospective population-based cohort study was performed using linked Surveillance, Epidemiology and End Results (SEER)-Medicare data to identify 11,084 Medicare beneficiaries aged ≥65 years who presented with Stage IV NSCLC in the 11 SEER regions between 1991 and 1996. The primary outcome was receipt of RT. Logistic regression analysis was used to identify factors associated with receipt of RT. Results: A total of 58% of these patients received RT, with its use decreasing over time (p = 0.01). Increasing age was negatively associated with receipt of treatment (p <0.001), as was increasing comorbidities (p <0.001). Factors positively associated with the receipt of RT included income (p = 0.001), hospitalization (p <0.001), and treatment with chemotherapy (p <0.001). Although the use varied across the SEER regions (p = 0.001), gender, race/ethnicity, and distance to the nearest RT facility were not associated with treatment. Conclusions: Elderly patients with metastatic NSCLC frequently receive palliative RT, but its use varies, especially with age and receipt of chemotherapy. Additional research is needed to determine whether this variability reflects good quality care
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2007.04.059Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2007.04.059;
- PII
- S0360-3016(07)00818-8;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 69
- Journal Issue
- 4
- Journal Page Range
- p. 1001-1007
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 39059609
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; CHEMOTHERAPY; EPIDEMIOLOGY; INCOME; LUNGS; METASTASES; PATIENTS; RADIOTHERAPY; REGRESSION ANALYSIS; SYMPTOMS
- Descriptors DEC
- BODY; DISEASES; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RESPIRATORY SYSTEM; STATISTICS; THERAPY
Optional Information
- Copyright
- Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.